S D Li1, J H Shi1, X J Li2. 1. Clinical Pharmacy, Department of Medicine, Linyi City Cancer Hospital of Shandong Province, Linyi 276001, China. 2. Department of Neurosurgery, National Cancer Center/Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021 China.
Abstract
OBJECTIVE: To analyze the preventive effect of mecobalamin combined with glutathione on neurotoxicity induced by FOLFOX4 chemotherapy. METHODS:Ninety-four patients receiving FOLFOX4 chemotherapy between January 2012 and December 2013 were randomized into experimental group and control group. Patients in the experimental group were given mecobalamin tablets and glutathione injection during chemotherapy while the patients in control group received glutathione injection only. The status of neurotoxicity was evaluated by the Levi neurotoxicity criteria 1992. RESULTS: After six cycles of chemotherapy, the incidence of grade Ⅰ-Ⅱ neurotoxicity in the experimental and control groups were 34.7% (17/49) and 55.6%(25/45), respectively (P=0.042), the incidence of grade Ⅲ neurotoxicity in the experimental and control groups were 2.0%(1/49) and 13.3%(6/45), the difference is also statistically significant (P=0.037). After nine cycles of chemotherapy, significantly less grade Ⅰ-Ⅱ neurotoxicity was observed in the experimental group (44.6%) than that in the control group(70.3%, P=0.019). Incidence of grade Ⅲ neurotoxicity in the experimental group was significantly lower(4.26%) than that in the control group(18.9%, P=0.031). CONCLUSION:Mecobalamin combined with glutathione can significantly reduce the incidence and severity of neurotoxicity induced by FOLFOX4 chemotherapy, therefore, worthy of clinical application.
RCT Entities:
OBJECTIVE: To analyze the preventive effect of mecobalamin combined with glutathione on neurotoxicity induced by FOLFOX4 chemotherapy. METHODS: Ninety-four patients receiving FOLFOX4 chemotherapy between January 2012 and December 2013 were randomized into experimental group and control group. Patients in the experimental group were given mecobalamin tablets and glutathione injection during chemotherapy while the patients in control group received glutathione injection only. The status of neurotoxicity was evaluated by the Levi neurotoxicity criteria 1992. RESULTS: After six cycles of chemotherapy, the incidence of grade Ⅰ-Ⅱ neurotoxicity in the experimental and control groups were 34.7% (17/49) and 55.6%(25/45), respectively (P=0.042), the incidence of grade Ⅲ neurotoxicity in the experimental and control groups were 2.0%(1/49) and 13.3%(6/45), the difference is also statistically significant (P=0.037). After nine cycles of chemotherapy, significantly less grade Ⅰ-Ⅱ neurotoxicity was observed in the experimental group (44.6%) than that in the control group(70.3%, P=0.019). Incidence of grade Ⅲ neurotoxicity in the experimental group was significantly lower(4.26%) than that in the control group(18.9%, P=0.031). CONCLUSION:Mecobalamin combined with glutathione can significantly reduce the incidence and severity of neurotoxicity induced by FOLFOX4 chemotherapy, therefore, worthy of clinical application.